SCF-FBXO31 E3 ubiquitin ligase in cancer: Molecular insights and clinical implications
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026
DOI: 10.1016/j.bbcan.2026.189534 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026. Verfasst von Osheen Sahay und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Neoplasms, Tumor Suppressor Proteins, SKP Cullin F-Box Protein Ligases, F-Box Proteins. Die Arbeit nennt 140 Literaturangaben.
Abstract (Originalsprache)
F-box only protein 31 (FBXO31), a substrate adapter of SKP1-Cullin1-F-box (SCF) E3 ubiquitin ligase, was first identified as a candidate tumor suppressor in breast cancer due to its role in inducing senescence. Over the past two decades, FBXO31 has emerged as a crucial regulator in several human cancers, where it promotes the proteasomal degradation of various oncoproteins. FBXO31 plays a crucial role in regulating the cell cycle to maintain genomic integrity and inhibits processes such as epithelial-to-mesenchymal transition (EMT), invasion, and metastasis. This review examines the molecular mechanisms underlying the potent tumor-suppressive functions of FBXO31 in diverse human cancers. We also discuss the underlying causes of FBXO31 deregulation in cancer, providing insights into the intricate regulatory networks governing its expression. Additionally, we also examine the unexpected oncogenic functions of FBXO31 in certain cellular contexts. Finally, we highlight the clinical potential of FBXO31 in human malignancies, discussing its implications as both a biomarker and a therapeutic target. In conclusion, understanding the nuanced biology of FBXO31 is crucial for unravelling its role in tumorigenesis and advancing future therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Maharashtra 410210, India.
- Cancer and Translational Research Centre, Dr. D.Y. Patil Biotechnology and Bioinformatics Institute, Dr. D.Y. Patil Vidyapeeth (DPU), Tathawade, Pune, Maharashtra 411033, India.
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02215, USA. Electronic address: ganesh_barik@dfci.harvard.edu.
- Department of Cancer Biology, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: sehbanul.islam@pennmedicine.upenn.edu.
Zitieren
APA
Sahay, O., Behera, A., Biswas, C., Barik, G. K., & Islam, S. (2026). SCF-FBXO31 E3 ubiquitin ligase in cancer: Molecular insights and clinical implications. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2026.189534
Vancouver
Sahay O, Behera A, Biswas C, Barik GK, Islam S. SCF-FBXO31 E3 ubiquitin ligase in cancer: Molecular insights and clinical implications. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026. doi:10.1016/j.bbcan.2026.189534
BibTeX
@article{Sahay2026,
author = {Sahay, Osheen and Behera, Abhayananda and Biswas, Chandra and Barik, Ganesh Kumar and Islam, Sehbanul},
title = {SCF-FBXO31 E3 ubiquitin ligase in cancer: Molecular insights and clinical implications},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
doi = {10.1016/j.bbcan.2026.189534}
}
EUVIMED